JRS Specialty Products Facility in China Awarded EXCiPACT Certification

25. Jul 2017

JRS PHARMA is pleased to announce that its Star-Tech & JRS Specialty Products excipients manufacturing site in Chongqing, China, has been awarded EXCiPACT certification.

The certification ensures via third-party inspection, evaluation, and auditing that the facility meets all of EXCiPACT’s criteria for good manufacturing practice (GMP) standards.

Star-Tech & JRS Specialty Products’ state-of-the-art GMP-compliant production facility is the result of a 2016 joint venture between JRS PHARMA and Chinese company, SSP. The site specializes in the manufacture of high-quality povidones for life sciences applications. These products include: 

  • VIVAPHARM® PVP (Povidone), the classic wet binder with optimal balance between adhesive strength and ease of handling.
  • VIVAPHARM® PVP/VA 64 (Copovidone), the ultimate tablet binder for all processing technologies.
  • VIVAPHARM® PVPP (Crospovidone), offering unsurpassed disintegration performance and versatility.


EXCiPACT provides a credible, high-quality, third-party scheme that allows manufacturers, suppliers, and distributors of pharmaceutical excipients worldwide to prove they have adopted best practices within their quality management systems. A not-for-profit organization, EXCiPACT is registered in Brussels, Belgium. 


JRS Pharma is a leading manufacturer of excipients, offering a complete portfolio of solutions for the global health science industry. Its excipients portfolio includes: high-functionality excipients, binders, disintegrants, lubricants, functional fillers, thickeners, stabilizers, carriers, and coatings. In addition to a wide range of excipients, they offer excellent technical support and biopharma services to address the needs and formulation challenges of their customers.

Privacy Policy

We Value Your Privacy

This website uses external tools and components to provide you the best experience on our website. You will find more detailed information in our privacy policy.